MedTrace Logo

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

NCT04329728 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2026-04-15

No results posted yet for this study

Summary

This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.

Conditions

  • Lymphoid Malignancies

Interventions

DRUG

AVM0703

Intravenous infusion over \~1 hours

Sponsors & Collaborators

  • Medpace, Inc.

    collaborator INDUSTRY

  • AVM Biotechnology Inc

    lead INDUSTRY

Principal Investigators

  • Elizabeth Budde, MD · City of Hope Medical Center

  • Gary Schiller, MD · University of California, Los Angeles

  • Tamra Slone, MD · U Texas SouthWestern

  • Don Stevens, MD · Norton Cancer Institute

  • Lasika Seneviratne, MD · Los Angeles Cancer Network

  • Pamela Miel, MD · Innovative Clinical Research Institute

  • Stefano Tarantolo, MD · Nebraska Cancer Specialists

  • Daniel Kerr, MD · ASCLEPES Research Centers

  • Nashat Gabrail, MD · Gabrail Cancer Center Research

  • Paul Rubinstein, MD · University of Illinois at Chicago

  • Salil Goorha, MD · Memphis Baptist Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-06
Primary Completion
2027-11-30
Completion
2028-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04329728 on ClinicalTrials.gov